Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
Galafold Expansion Continues with 360+ Fabry Patients Treated Today - on Track to Achieve FY18 Revenue Guidance of $75M-$85M Significant Progress Across Pompe Clinical, Regulatory and Manufacturing Activities - Successfully Completed First GMP Manufacturing Campaign of ATB200 Drug Substance at
View HTML
Toggle Summary Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives to Change People’s Lives Living with Rare Diseases
Unique Volunteerism, Mentorship, Giving, Global Access and Advocacy Programs Under Long-term Healing Beyond Disease Initiatives CRANBURY, N.J. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is honoring Rare Disease Day this week with the launch of Healing Beyond Disease™, a
View HTML
Toggle Summary Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 19,354,839 shares in the offering at a price of $15.50 per share.
View HTML
Toggle Summary Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
CRANBURY, N.J. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2017 . The call will be hosted by John F.
View HTML
Toggle Summary Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting
View HTML
Toggle Summary Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint lead book-running managers, Cowen and
View HTML
Toggle Summary Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
CRANBURY, N.J. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY on
View HTML
Toggle Summary U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Six-Month PDUFA Goal Date is August 13, 2018 CRANBURY, N.J. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision
View HTML
Toggle Summary Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™
         Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Out to Month 12 Very Low Rate (
View HTML
Toggle Summary Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
CRANBURY, N.J. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee (CDEC)’s positive recommendation of Galafold™ (migalastat) for listing with provincial drug formularies.
View HTML